Sökning: onr:"swepub:oai:DiVA.org:kau-80671" >
Immune function and...
Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer
-
- Matikas, A. (författare)
- Karolinska Institutet
-
- Lovrot, J. (författare)
- Karolinska Institutet
-
- Ramberg, A. (författare)
- Cent Hosp Karlstad
-
visa fler...
-
- Eriksson, M. (författare)
- Cent Hosp Karlstad
-
- Lindsten, T. (författare)
- Cent Hosp Karlstad
-
- Lekberg, T. (författare)
- Karolinska Institutet
-
- Hedenfalk, I. (författare)
- Lund University
-
- Loman, N. (författare)
- Lund University
-
- Bergh, J. (författare)
- Karolinska Institutet
-
- Erlandsson, Ann, 1968- (författare)
- Örebro University
-
- Hatschek, T. (författare)
- Karolinska Institutet
-
- Foukakis, T. (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- Oxford University Press, 2017
- 2017
- Engelska.
-
Ingår i: Annals of Oncology. - : Oxford University Press. - 0923-7534 .- 1569-8041. ; 28
- Relaterad länk:
-
https://urn.kb.se/re...
Abstract
Ämnesord
Stäng
- BackgroundGene expression (GE) signatures and Tumor Infiltrating Lymphocyte (TILs) enumeration have shown promise as predictors of response to neoadjuvant chemotherapy in Hormone Receptor negative (HR-) and HER2+, but not in HR+/HER2- breast cancer (BC). This study aimed to explore their predictive value in HR+/HER2- BC, based on previous work from our group on the association of immune function and chemosensitivity in advanced HR+ BC.MethodsThe PROMIX phase 2 trial enrolled patients with locally advanced HER2- BC to receive six cycles of epirubicin and docetaxel, plus bevacizumab during cycles 3-6. Patients underwent tumor biopsies at baseline and after cycle 2 for GE profiling using DNA microarrays and TIL enumeration according to standard guidelines. Since pathologic complete remission (pCR) is relatively rare in HR+ BC, we also associated an immune gene module score (IMS) and TIL counts with the non-dichotomous variable of decrease in tumor size.ResultsOf the 150 enrolled patients, n = 113 were HR+. For n = 71, both TIL and GE data were available at baseline, while for n = 78 and n = 49 patients longitudinal TIL and GE data at baseline and cycle 2 were available, respectively. At baseline, on both univariate (OR = 2.29, P = 0.037) and multivariate analysis (OR = 2.35, P = 0.044) IMS was associated with pCR, while its association with tumor shrinkage was only apparent on univariate (P = 0.047) and not multivariate analysis (P = 0.061). TIL infiltration >50% (n = 9) was associated with neither pCR (OR = 1.812, P = 0.61) nor tumor shrinkage (P = 0.99). However, decreases in TIL counts in cycle 2 compared with baseline were associated with lesser decreases in tumor size (P = 0.043 for univariate and P = 0.044 for multivariate analysis).
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Biology
- Biologi
Publikations- och innehållstyp
- vet (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Matikas, A.
-
Lovrot, J.
-
Ramberg, A.
-
Eriksson, M.
-
Lindsten, T.
-
Lekberg, T.
-
visa fler...
-
Hedenfalk, I.
-
Loman, N.
-
Bergh, J.
-
Erlandsson, Ann, ...
-
Hatschek, T.
-
Foukakis, T.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Annals of Oncolo ...
- Av lärosätet
-
Karlstads universitet